西班牙专利ES2648235T9 Compositions for oral care

专利PDF首页>>西班牙专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:

公开号:ES2648235T9
申请号:ES14705958.8T
申请日:2014-02-11
公开日:2018-07-16
发明作者:Frank Sun；Daniel Queiroz
申请人:Johnson and Johnson Consumer Inc；
IPC主号:

专利说明:

5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
Compositions for oral care Description
FIELD OF THE INVENTION
The present invention relates to oral compositions, which comprises selecting polyethylene oxide-polypropylene oxide block copolymer surfactants. The methods for using the compositions are also disclosed.
BACKGROUND OF THE INVENTION
GNPD Mintel Database: June 1, 2010, "Mouthwash" (Access to database N ° 1343978) refers to a commercial mouthwash containing cetylpyridinium chloride.
GNPD Mintel Database: December 1, 2005, "Mouthwash" (Access to database N ° 10244301) refers to a commercial mouthwash containing alcohol.
GB 2142536 A refers to a dentifrice containing maltitol as a humectant.
EP 2401999 A2 refers to mouthwashes with bioactive essential oils without alcohol.
US 2004/018154 A1 refers to oral care compositions comprising tropolone compounds.
WO 02/07691 A2 refers to compositions for inhibiting plaque and removing stains on teeth.
The formation and stabilization of colloidal dispersion systems has been studied extensively. The stability of these systems can be improved by adding a surface active agent or surfactant to modify the interfacial interactions between the system components. In the selection of surfactants for such systems, the hydrophilic-lipophilic surfactant balance (BHL) is traditionally considered. The BHL scale is based on the relative percentage of hydrophilic and lipophilic groups in the surfactant molecule. For example, an oil-in-water (A / A) emulsion will require a high BHL value (for example, 10-18) to stabilize the molecules in water. However, the BHL scale itself fails to indicate whether a specific surfactant will be effective as a delivery agent for active ingredients. In such situations, where the colloidal dispersion system includes active ingredients, the structure of the surfactant molecule should also be considered.
When present, micelles in a colloidal dispersion system exist in dynamic equilibrium where the rate at which surfactants exchange (or move) between the continuous phase and the micelle phase varies depending on the structure of the surfactant molecule. This speed, in turn, affects the ability of the active ingredient to disperse inside and outside the micelles. Without being limited to theory, it is believed that the efficacy of an active ingredient is linked to the ability of the active ingredient to disperse outside the micelles; more specifically, it is believed that the size of hydrophobic chains (for water-in-oil systems) or hydrophilic chains (for oil-in-water systems) of surfactants controls the ability of the active ingredient, solubilized in a micelle core, to disperse within or outside the micelle.
US Patent Publication 2012/0003163 A1 shows that poloxamers adversely affect the bioavailability of essential oils used as active ingredients. A non-limiting theory for this negative effect refers to the number of block units in such poloxamers and the proportion of polyethylene oxide (PEO) and polypropylene oxide (PPO) blocks, specifically poloxamers that have larger numbers of PPO blocks and a copolymer length greater than 30 units (blocks) produces a strong association (or increases strength) between the PPO blocks and the active ingredient, blocking the active ingredient in the micelle core and reducing bioavailability.
Due to such negative effects on the bioavailability of active ingredient, anionic surfactants such as sodium lauryl sulfate (SLS) are typically substituted by poloxamers. Such anionic surfactants produce little effect on the biodisonibility of active ingredients since they function as dispersants and not as emulsifiers for essential oils, which allows them to have less effect on bioavailability. In certain situations, however, the use of SLS may be limited in view of its irritating properties for skin / mucosa. Poloxamers, on the other hand, do not irritate the surfaces of the skin and mucosa. Therefore, there is still a need for poloxames that increase or otherwise improve the bioavailability of active ingredients such as essential oils.
The present inventors have discovered that PEO-PPO copolymers having a proportion of PEO and PPO blocks of from 0.8: 1 to 4: 1 reduce the association between the PpO blocks and the active ingredients, improving bioavailability.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
SUMMARY OF THE INVENTION
It has been discovered that the aforementioned objective can be achieved with the composition provided herein. In one embodiment, the present invention provides an oral composition comprising:
i. a polyethylene oxide-polypropylene oxide polque surfactant of the formula:
HO ------- (CH2CH2OH) x (CHCH20) and - (CH2CH20) x — H
CH3]
where "x" represents the average number of PEO units and is an integer from 10 to 100; "Y" represents the average number of PPO units and is an integer less than or equal to 30; and the ratio of "x" to "y" is 0.8: 1 to 4: 1 (or approximately 4: 1);
ii. one or more non-anionic bioactive agents having a log P greater than about 2; Y
iii. at least one orally acceptable solvent.
where the pH of the composition is maintained in a range below 5.
In more embodiments, the present invention relates to compositions such as those defined above for use in methods of treating plaque, gingivitis, pyorrhea or oral malodor, comprising the step of applying to the tissues (i.e., soft and hard) of the oral cavity of a mammal in need of such treatment the oral composition of the present invention in an amount effective to reduce or prevent tooth deterioration and / or reduce or prevent symptoms associated with plaque, gingivitis or pyorrhea.
In other embodiments, the present invention relates to compositions such as those defined above for use in methods of treating or reducing symptoms associated with inflamed tissue, which comprises the step of applying to the tissues of a mammal in need of such treatment a quantity of the Composition of the present invention effective to reduce the symptoms associated with inflammation.
In other additional embodiments, the present invention relates to compositions such as those defined above for use in methods for reducing the number of oral microorganisms responsible for plaque, gingivitis, pyorrhea or oral malodor, which comprises the step of applying to the tissues of a mammal having such microorganisms an amount of the composition of the present invention effective to reduce the number of such microorganisms.
DETAILED DESCRIPTION OF THE INVENTION
The composition of the present invention may comprise, consist of, or essentially consist of the essential elements and limitations of the invention described herein, as well as any of the additional or optional ingredients, components or limitations described herein. The terms "comprising" (and their grammatical variations) as used herein are used in the inclusive sense of "having" or "including" and not in the exclusive sense of "consisting solely of".
It is understood that the terms "un / a" and "el / la" as used herein encompass both the plural and the singular.
The phrase "orally acceptable" means that the transporter is suitable for application to the surfaces of the cavity or intake by a living organism that includes, but is not limited to, mammals and humans without toxicity, incompatibility, instability or excessive allergic response and Similar.
By "oral care composition" is meant a product that in the ordinary course of use is not intentionally swallowed for the purpose of systemic administration of particular therapeutic agents, but rather is retained in the oral cavity for a sufficient time to substantially contact with all dental surfaces and / or oral tissues in order to have oral activity. The oral care composition may have various forms including toothpaste, toothpaste, tooth gel, sub-gingival gel, mouthwash, solutions, mousse, foam, denture care product, mouth spray, chewable tablets or tablets. The oral care composition can also be incorporated into dental floss, strips or films for direct application or attached to oral surfaces or integrated into a device or applicator such as a toothbrush or ball dispenser. Such applicators can be single or multiple use.
The phrase "reduced level" or "essentially free" of alcohol means an amount of a C2-C4 monohydric alcohol of up to 10% w / w (or about 10% w / w), optionally, up to 5% w / w (or approximately 5% w / w), optionally up to 1.0% w / w (or approximately 1.0% w / w), optionally up to 0.1% w / w (or approximately
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
0.1% w / w) by volume of the total composition. Optionally, the compositions of the present invention are free of C2-C4 monohydric alcohols.
The terms "partition coefficient" means the Octanol-Water Partition Coefficient (Kow). Kow is the proportion of the concentration by weight of an oil or oily component in the octanol phase and the concentration by weight of the oil or oily component in aqueous phase in equilibrium and at a temperature specified for the biphasic octanol and water system. The log of Kow is called log P. The experimental values used to calculate the Kow are typically measured at a temperature between 20 ° C to 25 ° C.
Alternatively, log P values are conveniently calculated using the "C LOG P" program, also available in Daylights CIS. This program also lists experimental log P values when available in the Pomona92 database. The "calculated log P" (log PC) is determined by the technique of Hansch and Leo fragments (cf., A. Leo, in Comprehensive Medicinal Chemistry, Vol. 4, C. Hansch, PG, Sammens, JB Taylor and CA Ramsden, Eds., P. 295, Pergamon Press, 1990. The fragment technique is based on the chemical structure of each oil or oily component, and takes into account the number and types of atoms, the connectivity of the atom and chemical bond The log PC values, which are considered reliable and a widely used calculation for this physiochemical property, can be used instead of the experimental Kow method to measure the log P values. In certain embodiments, a calculated log P is obtained using the software of Hansen Solubility Parameters in Practice (HSPiP) 3rd edition (v 3.1.20) created by Charles M. Hansen, Steven Abbott and Hiroshi Yamamoto and available for online recovery at http://www.hansen-solubility.com/index.php id=16. The software calculates the P log values using the Molecular Break Yamamoto (Y-MB) method, which breaks the molecule into functional groups (ie, methyl or carbonyl) to calculate the log P value.
The higher the log P of a compound or component (for example, the non-anionic bioactive agent), the greater the degree of hydrophobicity of the compound or component.
The terms "non-anionic" as used herein mean that the bioactive agent is free of negatively charged fractions.
All percentages, parts and proportions are based on the total weight of the composition of the present invention, unless otherwise specified, all weights when they belong to the listed ingredients are based on the level of the particular ingredient described and, by therefore, it does not include conveyors or by-products that may be included in commercially available materials, unless otherwise specified.
The compositions of the present invention may be in the form of mouthwashes, dentifrices, toothpastes, gels, solutions or strips such as peroxide-free dental whitening strips and the like.
Polyethylene oxide-polypropylene oxide block copolymer surfactant
The poloxamers are copolymers of three non-ionic blocks composed of a polypropylene oxide hydrophobic central chain flanked by two hydrophilic polyethylene oxide chains. The poloxamers are also known by their trade name PLURONIC (BASF, Florham Park, N: J.).
The compositions of the present invention comprise a polyethylene oxide-polypropylene oxide block copolymer surfactant of the formula:
HO ------- {CH2CH, OH) x ----- (CHCH20) y— (CH2CH20) x — H
CH3
where "x" represents the average number of PEO units and is an integer from 10 to 100, optionally 10 to 80, or optionally 16 to 80; "Y" represents the average number of PPO units and is an integer less than or equal to 30, or optionally 16 to 30 and the ratio of "x" and "y" is not more than 4: 1 (or approximately 4 : 1), optionally 3: 1 (or approximately 3: 1), optionally 2.8: 1 (or approximately 2.8: 1), optionally 2: 1 (or approximately 2: 1), or optionally 1: 1 ( or about 1: 1), even the ratio of "x" to "y" is at least 0.8: 1 (or about 0.8: 1). In certain embodiments, the ratio of "x" to "y" is 2.7: 1 (or approximately 2.7: 1). In certain embodiments, the ratio of "x" to "y" is 1: 1 (or about 1: 1). Any of the polymers described herein with a structure not consistent with the above formula serves only as a reference and is not part of the invention.
These products are complex mixtures of copolymers reduced in a wide range of molecular weights (1,100-14,000) with various degrees of ethylene oxide and propylene oxide. The block polymers are
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
they prepare by polymerizing propylene oxide in a controlled manner to give a desired weight followed by ethoxylation with ethylene oxide. Examples of useful poloxamers include, but are not limited to:
Poloxamer PLURONIC “y” (Average number of PPO units) “x” (Average number of PEO units ”
108 F38 17.1 18.8
188 F68 29 76.4
238 F88 39.3 103.6
338 F108 50.3 132.7
407 F127 65.2 100.2
237 F87 39.8 61.3
335 P105 56 36.9
185 P65 29.3 19.3
More exposures of poloxamers can be found in: Batrakova et al., J. Pharmacol Exptl. Therapeu 2003, 304, pp. 845-854; U.S. Patent 6218438 to Alakhov et al., U.S. Patent 6849598 to Lambert, Jr .; Kabanov et al., Macromolecules 1995, 28, pp. 2303-2314; Varsheny et al., JACS 2004, 126, pp. 5108-5112; and Chiapetta and Sosnik, Eur. J. Pharm. Biopharm 2007, 66, pp. 3003-3017.
In certain embodiments, the poloxamer is selected from the group consisting of poloxamer 108, poloxamer 188 or mixtures thereof. In yet other embodiments, the poloxamer is poloxamer 188.
The PEO-PPO block copolymer surfactant may be present in concentrations of from
0.001% to 15%, optionally from 0.01% to 10%, optionally from 0.05% to 5%, or optionally from 0.1% to 3%.
Non-anionic bioactive agents
The compositions of the present invention also comprise a non-anionic bioactive agent. Typical examples of such agents, useful when considering effectiveness, safety and formulation in anti-caries, anti-plaque, anti-gingivitis or pyorrhea (or symptom reduction) treatment are:
1. Non-anionic anti-microbial bioactive agents such as:
2 ', 4,4'-trichloro-2-hydroxy-diphenyl ether (Triclosan) diphenyl ether
2- 2'-Dihydroxy-5-5'-dibromo-diphenyl ether HALOGENATED SALICILANILIDS 4'5-dibromosalicylanilide 3,4'5-trichlorosalicylanilide 3,4'5-tribromosalicylanilide 2,3,3'5-tetrachlorosalicylanilide 3,3 ' 5-tetrachlorosalicylanilide
3.5-dibromo-3'-trifluoromethyl salicylanilide 5-n-octanoyl-3'-trifluoromethyl salicylanilide
3.5- dibromo-4'-trifluoromethyl salicylanilide
3.5- dibromo-3'-trifluoromethyl salicylanilide (Fluorophene)
BENZOIC ESTERS
Methyl ester — p-Hydroxybenzoic acid Ethyl ester — p-Hydroxybenzoic acid Propyl ester — p-Hydroxybenzoic acid Butyl ester — p-Hydroxybenzoic HALOGENATED CARBANILIDS 3,4,4'-trichlorocarbanilide
3- trifluoromethyl-4,4'-dichlorocarbanilide 3,3'-4-trichlorocarbanlide
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
Phenolic compounds (including phenol and its homologues, mono and polyalkyl halo and aromatics (eg, F, Cl, Br, I) -phenols, resorcinol and catechol and their derivatives and bisphenolic compounds) such phenolic compounds include among others:
Phenol and its men Phenol
2 Methyl - Phenol
3 Methyl - Phenol
4 Methyl - Phenol 4 Ethyl — Phenol
2.4- Dimethyl-Phenol
2.5- Dimethyl-Phenol
3.4- Dimethyl-Phenol
2.6- Dimethyl-Phenol
4-n-Propyl — Phenol 4-n-Butyl — Phenol 4-n-Amyl — Phenol 4-tert-Amil — Phenol 4-n-Hexyl — Phenol 4-n-Hexyl — Phenol 4-n-Heptyl — Phenol
2- Methoxy-4- (2-Propenyl) -Phenol (Eugenol).
MONKEY- AND POLY- ARALQUILO RENT AND HALOPHENOLS
Methyl — p-Chlorophenol
Ethyl — p-Chlorophenol
n-Propyl — p-Chlorophenol
n-Butyl — p-Chlorophenol
n-Amil — p-Chlorophenol
sec-Amil — p-Chlorophenol
n-Hexil - p-Chlorophenol
Cyclohexyl - p-Chlorophenol
n-Heptyl - p-Chlorophenol
n-Octyl - p-Chlorophenol
O-Chlorophenol
Methyl - o-Chlorophenol
Ethyl - o-Chlorophenol
n-Propyl - o-Chlorophenol
n-Butyl - o-Chlorophenol
n-Amil - o-Chlorophenol
tert-Amil - o-Chlorophenol
n-Hexil - o-Chlorophenol
n-Heptyl - o-Chlorophenol
p-Chlorophenol
o-Benzyl - p-Chlorophenol
o-Benzyl-m-methyl - p-Chlorophenol
o-Benzyl-m, m-dimethyl - p-Chlorophenol
o-Phenylethyl - p-Chlorophenol
o-Phenylethyl-m-methyl - p-Chlorophenol
3- Methyl - p-Chlorophenol
3.5- Dimethyl - p-Chlorophenol 6-Ethyl-3-methyl - p-Chlorophenol 6-n-Propyl-3-methyl — p-Chlorophenol 6-iso-Propyl-3-methyl - p-Chlorophenol 2-Ethyl -3,5-dimethyl — p-Chlorophenol 6-sec Butyl-3-methyl - p-Chlorophenol 2-iso-Propyl-3,5-diemthyl - p-Chlorophenol 6-Diethylmethyl-3-methyl - p- Chlorophenol 6-iso-Propyl-2-ethyl-3-methyl - p-Chlorophenol 2-sec Amyl-3,5-dimethyl - p-Chlorophenol 2-diethylmethyl-3,5-dimethyl - p-Chlorophenol 6- sec Octyl-3-methyl - p-Chlorophenol p-Bromophenol
Methyl — p-Bromophenol Ethyl — p-Bromophenol n-Propyl — p-Bromophenol n-Butyl — p-Bromophenol
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
n-Amil — p-Bromophenol
sec-Amil — p-Bromophenol
n-Hexil — p-Bromophenol
cyclohexyl — p-Bromophenol
o-Bromophenol
tert-Amil — o-Bromophenol
n-Hexil — o-Bromophenol
n-Propyl-m, m-Dimethyl — or-Bromophenol
2-Phenyl Phenol
4-chloro-2-methyl phenol
4-chloro-3-methyl phenol
4- chloro-3,5-diemthyl phenol 2,4-dichloror-3,5-dimethylphenol
3,4,5,6-tetrabromo-2-methylphenol
5- methyl-2-pentylphenol
4- isopropyl-3-methylphenol
5- chloro-2-hydroxy diphenylethane RESORCINOL AND ITS DERIVATIVES Resorcinol
Methyl — Resorcinol
Ethyl — Resorcinol
n-Propil — Resorcinol
n-Butyl — Resorcinol
n-Amil — Resorcinol
n-Hexil — Resorcinol
n-Heptil — Resorcinol
n-Octil — Resorcinol
n-Nonil — Resorcinol
Phenyl — Resorcinol
Benzil — Resorcinol
Phenylethyl — Resorcinol
Phenylpropyl — Resorcinol
p-Chlorobenzyl — Resorcinol
5-Chlorine — 2,4-Dihydroxydiphenyl Methane
4'-Chlorine — 2,4-Dihydroxydiphenyl Methane
5-Bromo — 2,4-Dihydroxydiphenyl Methane
4'-Bromo — 2,4-Dihydroxydiphenyl Methane
BISPHENOLIC COMPOUNDS
Bisphenol A
2,2'-methylene bis (4-chlorophenol)
2,2'-methylene bis (3,4,6-trichlorophenol) (hexachlorophen)
2,2'-methylene bis (4-chloro-6-bromophenol) bis (2-hydroxy-3,5-dichlorophenyl) sulfide bis (2-hydroxy-5-chlorobenzyl) sulfide
Other non-anionic antimicrobial bioactive agents include, but are not limited to: hexetidine; Fatty acid compounds such as caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid, vitamin E, vitamin E, acetate, apigenin and mixtures thereof; Long chain fatty alcohols such as those described in US Patent Publication US 20110123462 of Mordars et al. (Examples of which include, but are not limited to 1-decen-3-ol; cis-4-decen-1-ol, trans-2-decen-1-ol, cis-2-nonen-1-ol, cis-4-decenial, trans-2-decennial, cis-7-decennial, cis-5-octen-1-ol, trans-2- octen-1-ol, 1-octen-3-ol, cis-3- nonen-1-ol, trans-2-nonen-1-ol, cis-6-nonen-1-ol, 9-decen-1-ol, trans-2-undecen-1-ol, trans-2-dodecen- 1-ol, trans-2-octenal, trans-2-nonenal, 6-nonenal, cis-2-decennial, trans-2-undecenal, trans-2- dodecenal, cis-3-octen-1-ol, 3- octen-2-ol, 10-undeen-1-ol, trans-2-tridecen-1-ol, stereoisomers thereof and mixtures thereof); Na-alkyl-L-arginine alkyl ester (for example, ethyl lauroyl arginine ester) and salts such as those described in US Pat. No. 5,874,068 to Engelman et al; and surfactants, which include cationic surfactants such as cetylpyridinium chloride, chlorhexidine and mixtures thereof. Oils such as peppermint oil and sage oil are also useful here.
Also useful non-anionic antimicrobial bioactive agents are one or more bioactive essential oils or mixtures thereof. Non-limiting examples of such essential oils include:
Thymol, [(CH3) 2CHC6H3 (CH3) OH, also known as isopropyl-m-cresol] is only slightly soluble in water but is soluble in alcohol.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
Methyl salicylate, [C6H4OHCOOCH3, also known as gaulteria oil], also provides flavor along with its antimicrobial function;
Eucalyptol (C10H18O, also known as cineole) is a terpene ether and provides a refreshing and spicy taste. Eucalyptol can be used instead of thymol in certain formulations in the same amount if desired; Y
Menthol (CH3C6Hg (C3H7) OH), also known as hexahydrotimol) is also only slightly soluble in alcohol, and is quite volatile. Menthol, in addition to antiseptic properties, provides a cooling and chilling sensation.
II. Non-anionic anti-inflammatory bioactive agents such as:
NFk-B inhibitor as substituted resorcinol (as 4-hexyl resorcinol and 4-octylresorcinol), (E) -3- (4- methylphenylsulfonyl) -2-propenonitrile (as "Bay 11-7082", commercially available from Sigma-Aldrich from St. Louis, Mo.), tetrahydrocurcuminoids (such as Tetrahydrocurcuminoid CG, available from Sabinsa Corporation of Piscataway, NJ), wood extracts of Paulownia tomentosa, and combinations thereof; bark extract of phelodendron amurense (PCE), matricaria (Tanacetum parthemium), ginger (Zingiber officinale), gingo (Ginko Biloba), cotinus (Cotinus coggygria), goji berry (Lycium bargbarum), milk thistle extract (Silybum marianum) , honeysuckle (Lonicera japan), balsam of Peru (Myroxylon pereirae), sage (Salvia officinalis), cranberry extract (Vaccinium oxycoccos), amaranth oil (Amaranthus cruentus), pomegranate (Punica granatum), yerba mate (Leaf extract Ilex paraguariensis), white water lily flower extract (Lilium Candidum), olive leaf extract (European Olea), florentine (apple extract), lifenol extract (hops: Humulus lupulus), licochalcone (licorice: Glycyrrhiza extract ingredient inflate), symrelief (bisabolol and ginger extract), Magnolo (bark extract of Houpu magnolia [Magnolia officinalis], Honokiol (pineapple extract, bark and leaves of Magnolia grandifloris) and mixtures thereof; anti-inflammation agents non-steroidal matoriums such as derivatives of salicylic acid (for example, aspirin), derivative of paraminophenol (for example, acetaminophen), indolacetic acid and indolacetic acid (indomethacin, sulindac and etodlac) acetic acids of heteroaryl (tometin, diclofenac and ketorolac), acid derivatives propinoic acid (ibuprofen, naproxen, ketoprofen, fenoprene, oxaprozin), anthranilic acid (mefenamic acid, meclofenamic acid), enolic acids (piroxicam, tenoxicam, phenylbutazone and oxifentatrazone) and mixtures thereof.
Other useful non-anionic bioactive agents can be found in U.S. Patent Publication 2007/0190080 by Doron Friedman and U.S. Patent Publication 20120003162 by Mordas et al.
Optionally, mixtures of any of the aforementioned compounds can be used as the non-anionic bioactive agent.
The non-anionic bioactive agent is present in the oral composition in an amount effective to achieve biological activity such as anti-inflammation, analgesic, anti-caries, anti-plaque, anti-gingivitis or reduction in pyorrhea symptoms. The effective amount of the non-anionic bioactive agent to i) treat or reduce inflammation or other symptoms of pyorrhea or ii) provide analgesia, anti-caries, anti-plaque, anti-gingivitis ranges from about 0.01%, optionally from about 0, 01% to about 5%, optionally from about 0.03% to about 1%, or optionally from about 0.03% to about 0.5%, by weight of the total composition. In certain embodiments, the non-anionic bioactive agent is insoluble in water, or substantially insoluble in water, which means that its solubility is less than about 1% by weight in water at 25 ° C or, optionally, less than about 0.1 %. In other embodiments, the non-anionic bioactive agent is defined in terms of the degree of hydrophobicity of the bioactive agent as measured by the partition coefficient (log P) for the non-anionic bioactive agent. In certain embodiments, the bioactive agent has a log P greater than 2 (or approximately 2), optionally greater than 3 (or approximately 3), or optionally greater than 3.5 (or approximately 3.5), but, optionally, less to 9 (or about 9) or, optionally, less than 7 (or about 7).
Table 1 provides the selection of non-anionic bioactive agents and their calculated log P value using the HSPiP software (v 3.1.20).
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
Table 1
Non-anionic bioactive agent Log P calculated
Menthol 2.89
Timol 3.23
Methyl salicylate 2.29
Eucalyptol 3.23
Triclosan 4.51
Cetylpyridinium Chloride 8.42
Hexetidine 5.98
Ethyl lauroyl arginine ester 5.31
Cis-2-none-1-ol 3.01
1-decen-3-ol 3.63
trans-2-dodecenal 4.75
cis-4-decennial 3.51
trans-2-decennial 3.70
In certain embodiments, bioactive essential oils are used in effective amounts to provide antimicrobial activity in the oral cavity. In certain embodiments, bioactive essential oils are used in effective amounts to provide analgesic or anti-inflammatory activity in the oral cavity. In specific embodiments, the total amount of bioactive essential oils present in the disclosed compositions may be from 0.001% (or about 0.001%) to 0.35% (or about 0.35%) w / v, or optionally from 0, 16% (or about 0.16%) to 0.28% (or about 0.28%) w / v of the composition.
In some embodiments, the composition of the present invention contains these four bioactive essential oils.
In certain embodiments, thymol is used in amounts of from 0.001% (or about 0.001%) to 0.25% (or about 0.25%) w / v, or optionally from 0.04% (or about 0.04% ) at 0.07% (or about 0.07%) w / v of the composition. In certain embodiments, eucalyptol is used in amounts of from 0.001% (or about 0.001%) to 0.11% (or about 0.11%) w / v, or optionally from 0.085% (or about 0.085%) to 0, 10% (or about 0.10%) w / v of the composition. In certain embodiments, menthol is used in amounts of from 0.001% (or about 0.001%) to 0.25% (or about 0.25%) w / v, or optionally from 0.035% (or about 0.035%) to 0, 05% (or about 0.05%) w / v of the composition. In certain embodiments, methyl silicylate is used in amounts of from 0.001% (or about 0.001%) to 0.08% (or about 0.08%) w / v, or optionally from 0.04% (or about 0, 04%) at 0.07% (or about 0.07%) w / v of the composition.
Orally acceptable solvent
The compositions of the present invention further comprise an orally acceptable solvent. Orally acceptable solvents include, but are not limited to, water, C2-C4 monohydric alcohols, polyethylene glycol and mixtures thereof. When present, C2-C4 monohydric alcohols are at a reduced level.
Optional components
In certain embodiments, the compositions of the present invention show a high level of antimicrobial activity as measured by an M factor greater than 0.5 (or about 0.5), optionally 1.0 (or about 1.0), optionally 2 , 0 (or approximately 2.0), or optionally 3.0 (or approximately 3.0) where the “M factor” is equal to the log value SUL (relative units of light) of water used as the negative control minus the value log URL of the mouthwash composition of the composition being tested. In other embodiments, the oral mouthwash compositions of this invention are clear (visually human) and aesthetically attractive products.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
The compositions of the present invention may further comprise optional components (collectively referred to as orally acceptable carriers or excipients) that are described in the following paragraphs together with non-limiting examples. These orally acceptable carrier materials include one or more solid or liquid compatible excipients or diluents that are suitable for oral topical administration. By "compatible" it is meant that the components of the composition are capable of being combined without interaction in such a way that the stability and / or efficiency of the composition is substantially reduced. Suitable carriers or excipients are well known in the art. Your selection will depend on secondary considerations such as taste, cost, shelf stability, etc. Although a general list of optional components is provided below, a more detailed discussion of suitable optional components (including excipients and carriers) can be found in U.S. Patent Publication 20110089073 by Baig et al .; U.S. Patent 5,599,527 to Hsu et al; and U.S. Patent Publication 20120003163 by Mordas et al.
Additional surfactant
In certain embodiments, the present invention contains a surfactant in addition to the PEO-PPO block polymer surfactant of formula I to aid in the solubilization of essential oils if present, as long as such additional surfactants do not affect the bioavailability of the oils essential. Suitable examples include anionic surfactants, nonionic surfactants, amphoteric surfactants and mixtures thereof.
Anionic surfactants useful herein include, but are not limited to, sarcosine or sarcosinate surfactants; taurates such as sodium methylcocoyl laurate; alkyl sulfate such as sodium trideceth sulfate or sodium lauryl sulfate; sodium lauryl sulfoacetate; sodium lauroyl isethionate; sodium laureth carboxylate; sodium dodecyl benzenesulfonate and mixtures thereof. Many suitable anionic surfactants are disclosed in U.S. Patent No. 3,959,458 to Agricola, et al.
Non-ionic surfactants that can be used in the compositions of the present invention include, but are not limited to, compounds produced by the condensation of alkylene oxide groups (hydrophilic by nature) with an organic hydrophobic compound that may be aliphatic or alkyl. aromatic by nature. Examples of suitable non-ionic surfactants include, but are not limited to, alkyl polyglucosides; hydrogenated and ethoxylated castor oils commercially available for example under the trade name CRODURET (Croda Inc., Edison, NJ), and / or ethoxylated fatty alcohol; polyethylene oxide condensates of alkyl phenols; products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene diamine; ethylene oxide condensates of aliphatic alcohols; long chain tertiary amine oxides; long chain tertiary phosphine oxides; long chain dialkyl sulfoxides; and mixtures thereof.
Amphoteric surfactants useful in the present invention include, but are not limited to, derivatives of secondary and tertiary aliphatic amines where the aliphatic radical can be a straight or branched chain and where one of the aliphatic substituents contains from about 8 to about 18 atoms of Carbon and one contains an anionic group that solubilizes in water, for example, carboxylate, sulphonate, sulfate, phosphate or phosphonate. Examples of suitable amphoteric surfactants include, but are not limited to, alkylimino diproprionates, alkylaphoglycinates (mono or di), alkylaphoproprionates (mono or di), alkynophoacetates (mono or di), N-alkyl p-aminopropionic acids, alkyl polyamino carboxylates , phosphorylated imidazolines, alkyl betaines, alkylamido betaines, alkylamidopropyl betaines, alkyl sultaines, alkylamido sultaines and mixtures thereof. In certain embodiments, the amphoteric surfactant is selected from the group consisting of alkylamidopropyl betaines, amphoacetates such as sodium lauroamphoacetate and mixtures thereof. Mixtures of any of the aforementioned surfactants can also be used. A more detailed discussion of anionic, non-ionic and amphoteric surfactants can be found in US Pat. Nos. 7,087,650 to Lennon; No. 7,084,104 by Martin et al .; No. 5,190,747 to Sekiguchi et al .; and No. 4,051,234 of Gieske et al.
The compositions of the present invention may also include one or more ingredients that include, without exclusion, a thickening agent, humectants, chelating agents, bleaching agents and additives such as colorants or dyes, flavorings, preservatives, pH adjusting agents, and the like. The pH of the compositions of this invention is maintained in the range of less than 5 (or about 5), optionally below 4.5 (or about 4.5) or, optionally in the range of from 4.4 (or about 4.4) to 3 (or about 3), or optionally in the range of from 3.5 (or about 3.5) to 4.2 (or about 4.2).
Commercially available thickening agents capable of imparting the appropriate viscosity to the compositions are suitable for use in this invention. Examples of suitable thickening agents include not exclusively: mono or diesters of 1) polyethylene glycol of the formula: HO- (CH2CH2O) zH, where z is an integer from about 3 to about 200; and 2) fatty acids containing from about 16 to about 22 carbon atoms; fatty acid esters of ethoxylated polyols; ethoxylated derivatives of mono and diesters of fatty acids and glycerin; hydroxyalkylcellulose; alkylcellulose; hydroxyalkyl alkyl cellulose; and mixtures thereof. Preferred thickeners include ester of
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
polyethylene glycol, and more preferably PEG-150 distearate which is available from Stepan Company of Northfield, Illinois or Comiel, S. p. A from Bologna, Italy under the trade name "PEG 6000 DS".
Commercially available humectants are suitable in the present invention. The humectant may be present in an amount of from about 0 percent to about 20%, optionally from about 0.5% to about 15%, or optionally from about 0.5% to about 10% based on the total weight of the composition. Examples of suitable humectants include without exclusivity: 1) water-soluble liquid polyols selected from the group comprising or consisting of sorbitol, glycerin, propylene glycol, hexylene glycol, butylene glycol, dipropylene glycol, and mixtures thereof; 2) polyalkylene glycol of the formula: HO- (R'O) bH, where R '' is an alkylene group having from about 2 to about 3 carbon atoms and b is an integer from about 2 to about 10 ; 3) polyethylene or methyl glucose glycol ether of the formula CH3-C6H1UO5- (OCH2CH2) c-OH, where c is an integer from about 5 to about 25; 4) urea; and 5) mixtures thereof. In certain embodiments, the humectant is a mixture of sorbitol and propylene glycol.
Examples of suitable chelating agents include those that are capable of protecting and preserving the compositions of this invention. Preferably, the chelating agent is ethylenediaminetetraacetic acid ("EDTA") and more preferably EDTA trisodium, commercially available from Dow Chemical Company of Midland, Michigan under the trade name "Versene 100XL" and is present in an amount, based on the total weight of the composition, from about 0 to about 0.5 percent, and preferably from about 0.05 percent to about 0.25 percent.
Suitable preservatives include sodium benzoate and polysorbate and are present in the composition in an amount, based on the total weight of the composition, from about 0 to about 0.2 percent, and preferably from about 0.05 percent to approximately 0.10 percent.
In certain embodiments, the compositions of the present invention are free or essentially free of compounds that affect bioavailability. As used herein, "compound that affects bioavailability" refers to compounds that negatively affect the bioavailability of any incorporated essential oil such as surrounding essential oils or otherwise inactivating essential oils. "Essentially free" as used herein with respect to compounds that affect bioavailability is defined as formulations having less than 5% (or about 5%), optionally 3% (or about 3%), optionally 1% (or about 1%) or optionally 0.1%, or optionally 0.01% (or about 0.01%) by weight (w / v) of the composition of a compound that affects bioavailability. In certain embodiments, the bioavailability-affecting compound may include, but is not limited to, polyethylene oxide / polypropylene oxide block copolymers that are outside the scope of formula I (as described above); cyclodextrins, polysorbates such as Tweens; and mixtures thereof.
The compositions described above can be prepared by combining the desired components in a suitable container and mixing them under ambient conditions using conventional mixing technology, which includes technology well known in the art, such as mechanically removing propeller, blade and the like. The mix order is not critical.
The invention disclosed herein illustratively can be suitably practiced in the absence of any component, ingredient or stage that is not specifically disclosed herein. Several examples are set out below to better illustrate the nature of the invention and how to carry it out. However, the invention should not be considered as limited to the details thereof.
EXAMPLES
The invention is defined in the appended claims, and any examples that are not included within the scope of the claims are references only. The following examples are formed using conventional mixing technology and are illustrative only and should be construed as limiting the invention in any way. In order to evaluate different poloxamer samples, the concentration of the poloxamer samples are normalized based on the contribution (ie, number) of hydrophobic units of PPO.
Without being limited to any theory, it is believed that the PPO hydrophobic unit segments interact with the non-anionic bioactive agent (e.g. essential oils) of the present invention to keep them emulsified and dispersed and the strength of this interaction (or the number of interacting PPO units) determines whether the non-anionic bioactive agent becomes inactive (that is, binds) or is allowed to remain ineffective (that is, is released or substantially released). Thus, the concentration of all the poloxamer samples per formulation is adjusted to provide a hydrophobicity equal to that of approximately 1.5% by weight of poloxamer F68, which allows a comparison of the relative amounts of various poloxamers required to achieve efficacy ( that is, interaction of essential oil similar to that of poloxamer F68 This concentration of 1.5% by weight of poloxamer F68 was chosen as the standard concentration of formula made since formulations
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
containing such a concentration of poloxamer F68 show good efficacy (see results of Example I). The formulations A-D, G-I, K and M are for reference only, since they are indicated with * in the following examples.
Example I
Ingredients A * (% w / w) B * (% w / w) C * (% w / w) D * (% w / w) E (% w / w) F (% w / w) G * (% p / p) H * (% p / p)
USP Propylene Glycol 7,000000 7,000000 7,000000 7,000000 7,000000 7,000000 7,000000 7,000000
USP benzoic acid 0.085900 0.085900 0.085900 0.085900 0.085900 0.085900 0.085900 0.085900
Menthol, USP 0.041262 0.041262 0.041262 0.041262 0.041262 0.041262 0.041262 0.041262
Timol, NF 0.062039 0.062039 0.062039 0.062039 0.062039 0.062039 0.062039 0.062039
Methyl Salicylate, NF 0.064078 0.064078 0.064078 0.064078 0.064078 0.064078 0.064078 0.064078
Eucalyptol, USP 0.089515 0.089515 0.089515 0.089515 0.089515 0.089515 0.089515 0.089515
Purified water 77.509307 77.509307 77.509307 77.509307 77.509307 77.509307 77.509307 77.509307
USP sodium saccharin, qranular 0.060600 0.060600 0.060600 0.060600 0.060600 0.060600 0.060600 0.060600
Sucralose Powder, NF 0.010000 0.010000 0.010000 0.010000 0.010000 0.010000 0.010000 0.010000
Sodium Benzoate, NF 0.077300 0.077300 0.077300 0.077300 0.077300 0.077300 0.077300 0.077300
70% sorbitol solution, USP 10,000000 10,000000 10,000000 10,000000 10,000000 10,000000 10,000000 10,000000
PLURONIC F 108    0.863010
PLURONIC F 88      1,10526
PLURONIC F87        1,09091
PLURONIC F 68          1,50000
PLURONIC F 127 0.66667
PLURONIC F 38            2,80000
PLURONIC P 105              0.77538
PLURONIC P 65                1.44000
Purified water QS up to 100% QS up to 100% QS up to 100% QS up to 100% QS up to 100% QS up to 100% QS up to 100% QS up to 100%
The procedure for mixing the formulations of Example 1 is as follows:
In an appropriate container, an aqueous phase is prepared by adding water, saccharin, sucralose and sodium benzoate and mixing until the ingredients dissolve and the solution becomes uniform and homogeneous. Then, the sorbitol solution is added and mixed until the solution becomes uniform and homogeneous.
In a suitable separate container, a glycol solution is prepared by adding separately, with mixing until dissolved, each of propylene glycol, benzoic acid, menthol and thymol. Then, methyl silicilate and equualiptol are added and mixed for 5 minutes or until a uniform and homogeneous solution is achieved.
To the aqueous solution, the poloxamer is added by mixing until a uniform and homogeneous solution is achieved. Then glycol solution is added by mixing until the solution becomes uniform and homogeneous. Additional water is added when necessary to QS at appropriate levels. The pH is adjusted to 4.2 ± 0.1 with minimal amounts of HCl or NaOH as necessary. The turbidity of each of the AH formulations is measured using a Model 2100N Laboratory Turbidometer from Hach Company (Loveland, CO).
A-H formulations are also tested using a single biofilm model of the species S. mutans in-vivo. The S. mutants biofilm grows (N = 96) and is exposed to the formulations as well as positive and negative controls for 30 seconds. Sterile water was used as a negative control. After treatment the biofilm is neutralized and rinsed. The biofilm is harvested by sonication using an Misonix XL_2000 ultrasonic processor (Qsonica, LLC, Newtown, CT). Using a Celsis Rapid Detection RapiScreen kit (Celsis International PLC,
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
Chicago), the bacterium was broken with Celsis Luminex and the ATP of the bacteria was measured using the Celsis LuminATE bioluminescence marker. The decrease in log URLs (Relative Units of Light) indicates that there are fewer live bacteria after treatment. Sterile water is used as the negative control and, using the above method, it was determined that log URL was 7.74.
A * (% w / w) B * (% w / w) C * (% w / w) D * (% w / w) E (% w / w) F (% w / w) G * (% p / p) H * (% p / p)
pH 4.11 4.15 4.13 4.2 4.17 4.12 4.18 4.19
Turbidity (NTU) 10.8 9.88 5.71 5.5 6.19 3994 12.2 469
URL log 7.45 7.29 7.37 7.52 6.81 6.76 7.77 7.88
M factor 0.29 0.45 0.37 0.22 0.93 0.98 -0.03 -0.14
Example II
Ingredient Comparative Example Toothpaste of essential oil (% w / w) Inventive Example I * of toothpaste (% w / w) Inventive Example J of toothpaste (% w / w)
NF methyl salicylate 0.051600 0.051600 0.051600
Eucalyptol 0,77450 0,77450 0,77450
Flavoring 0.22500 0.22500 0.22500
Timol NF 0.51120 0.51120 0.51120
USP Menthol 0.34000 0.34000 0.34000
Purified water 24,49855 21.22347 14.97347
Sorbitol solution 40.00000 40.00000 40.00000
Color 0.0025 0.00000 0.00000
Phosphate disodium 0.03000 0.03000 0.03000
USP sodium monofluorophosphate 0.76000 0.76000 0.76000
USP Granular Sodium Saccharin 1,2000 1,2000 1,2000
Anhydrous monobasic sodium phosphate 0.25000 0.25000 0.25000
32 NF polyethylene glycol 3,00000 3,00000 3,00000
Benzoic acid 0.15000 0.15000 0.15000
NF phosphoric acid 0.44250 0.44250 0.44250
Hydrated silicon dioxide 7.00000 7.00000 7.00000
Amorphous Silicon Sylodent 750 11.00000 11.00000 11.00000
USP glycerin, 96% 6,00000 - -
USP glycerin, 99.7% - 5,77733 5,77733
Sodium carboxymethylcellulose (CMC) 1,200000 1,200000 1,200000
Xantana K6B166 rubber 0.25000 0.25000 0.25000
Titanium dioxide 0.35000 0.35000 0.35000
PLURONIC F127 - 5,00000 -
PLURONIC F68 - - 11.25000
Sodium lauryl sulfate W&D 1,50000 - -
Total 100,00000 100,00000 100,00000
The procedure for mixing the toothpaste formulations of Example II is as follows:
In a suitable container, a flavoring mixture is prepared by adding the following ingredients by mixing the methyl salicylate, flavoring, thymol and menthol. The container is covered to prevent loss of flavor. Just before the transfer, eucalyptol is added and the mixture is combined until a uniform and homogeneous solution is achieved.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
In a suitable container, a wetting phase is prepared by adding the following ingredients by mixing the glycerin and CMC sodium. The wetting phase is mixed until it becomes uniform and homogeneous. Then, xanthan gum is added and mixed until the phase mixture becomes uniform and homogeneous.
In an appropriate container, an aqueous phase is prepared by adding the following ingredients by mixing the purified water, PLURONIC and sorbitol. The aqueous phase is mixed until it becomes uniform and homogeneous. Then, USP sodium monofluorophosphate, sodium saccharin, anhydrous sodium (monobasic) phosphate, dibasic sodium phosphate (anhydrous), 32 NF polyethylene glycol, USP benzoic acid are added and mixed for approximately 10 minutes until the mixture of the phase is uniform and homogeneous. Phosphoric acid is added and mixed until the phase mixture is uniform and homogeneous.
In the container containing the aqueous phase, the wetting phase is added by mixing until it becomes uniform and homogeneous. Titanium dioxide is added to the mixture and mixed until the mixture is uniform and white. The mixture is transferred to a Ross mixer (Model No. DPM-1QT, Charles Ross & Son Company [Hauppauge, New York]) and Zeosyl 200 is added. The mixture is mixed at 15 RPM for approximately 2 minutes until the powders are impregnate The mixture is then mixed at 40-50 RPM for approximately 5 minutes under vacuum. Sylodent 750 is added to the mixture and mixed at 15 PRMP for approximately 2 minutes until the powders are impregnated. The mixture is then mixed at 40-50 RPM for approximately 5 minutes under vacuum. The flavoring mixture is added to the mixture and mixed at 25 RPM for approximately 2 minutes until the flavorings are dispersed uniformly. The mixture is placed under vacuum and mixing is continuous for about 15 to about 20 minutes until the paste is of an appropriate consistency. Once consistency is achieved, the mixture is stopped, the vacuum is removed and the toothpaste is dispensed into main packaging tubes.
A kinetics test with ex vivo elimination is performed using convention testing methodology to evaluate the antimicrobial effect of the various poloxamers in the toothpaste formulations of Example II. The test included tests of the toothpaste formulation of Example II against human saliva accumulated ex vivo at exposure times of 30 seconds and 1 minute to understand the differences between PLUROFONIC F127 and PLURONIC F68. A toothpaste with commercial essential oil was included as a positive control in the trial. Sterile water was used as a negative control in the test.
Method:
• A sample is weighed in a sterile test tube containing three drops of glass;
• Accumulated human saliva is added to the test tube and removed;
• At 30 and 60 seconds an aliquot is taken and neutralized to stop the activity of antimicrobials;
• Serial dilutions are prepared and the sample is placed on plates in tryptic soy agar (AST) with 5% sheep blood with vitamin K-hemin for total counts of microorganisms and oral sulfide agar that produces organisms (OOP) III for counts of microorganisms with a bad smell.
• After incubation, the total recoverable colonies are listed and compared with units that form colonies in a negative control group.
• Samples are tested in triplicate; The results represent the average of the three repetitions.
The results of the kinetics test with ex vivo removal are shown in Table 2 (as% reduction from sterile water).
Table 2
Essential oil mouthwash (% reduction vs. sterile water) I * (% reduction vs. sterile water) J (% reduction vs. sterile water)
Counts associated with bad smell in OOPs III agar 0.5 minute 99.9% 99.9% 99.9%
1.0 minute 99.9% 99.9% 99.9%
Total TSA counts with 5% sheep blood agar with HK 0.5 minute 99.9% 97.5% 99.9%
1.0 minute 99.9% 94.2% 99.9%
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
Example III
More experiments were performed with mouthwashes to validate the principle that governs the ability of non-ionic surfactanes to function as an effective on-site delivery agent for non-anionic bioactive agents. The results below demonstrate the effectiveness of poloxamers that have less than 30 units of polypropylene oxide blocks. Table 3 shows the improved performance for formulations free of and / or essentially free of sLs and containing an antimicrobially effective amount of one or more bioactive essential oil agents.
Table 3
Negative control Positive control (commercially available essential oil mouthwash) K * L M * N
Ingredients (% w / w) (% w / w) (% w / w) (% w / w) (% w / w) (% w / w)
USP purified water 100,000 82.0950 80.4450 80.9450 81.9830 80.9950
PLURONIC F127 - 0.2000 2.0000 - 0.500 -
PLURONIC F68 - - - 1,5000 - 1,5000
Sodium Lauryl Sulfate - 0.2000 0.0500 0.0500 0.0120 -
Sodium benzoate - 0.0773 0.0773 0.0773 0.0773 0.0773
Sweetener - 0.0706 0.0706 0.0706 0.0706 0.0706
Propylene Glycol - 7,0000 7,0000 7,0000 7,0000 7,0000
Benzoic acid - 0.0859 0.0859 0.0859 0.0859 0.0859
Menthol - 0.0385 0.0385 0.0385 0.0385 0.0385
Timol - 0.0620 0.0620 0.0620 0.0620 0.0620
Eucalyptol - 0.0895 0.0895 0.0895 0.0895 0.0895
Methyl salicylate - 0.0641 0.0641 0.0641 0.0641 0.0641
Flavoring - 0.0170 0.0170 0.0170 0.0170 0.0170
Sorbitol (70% solution) - 10,0000 10,0000 10,0000 10,0000 10,0000
Color - 0.000020 - - - -
Total 100 100 100 100 100 100
pH - - 4.22 4.21 4.22 4.22
Turbidity (NTU) - - 4.96 2.47 11.4 7.51
URL log 7.81 5.72 7.79 6.88 7.29 6.93
M factor 0 2.09 0.02 0.93 0.52 0.88
Example IV
Examples of O-R mouth rinses further illustrate the present invention (that is, compositions containing the selected non-anionic bioactive agents and poloxamers as described above) and include the following:
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
O P Q R
Ingredients (% p / p) (% P / P) (% P / P) (% P / P)
USP purified water Q.S Q.S Q.S Q.S
PLURONIC F38 - - 2,8000 2,8000
PLURONIC F68 1,5000 1,5000 - -
Sodium benzoate 0.0773 0.0773 0.0773 0.0773
Sweetener 0.0706 0.0706 0.0706 0.0706
Propylene Glycol 7,0000 7,0000 7,0000 7,0000
Benzoic acid 0.0859 0.0859 0.0859 0.0859
Cetylpyridinium Chloride 0.01 to 0.1 - 0.01 to 0.1 -
Ethyl lauroyl arginine ester - 0.05 to 0.5 - 0.05 to 0.5
Flavoring 0.0170 0.0170 0.0170 0.0170
Sorbitol (70% solution) 10,0000 10,0000 10,0000 10,0000
Total 100 100 100 100
Non-anionic bioactive agents, cetylpyridinium chloride and ethyl lauroyl arginine ester can also be incorporated into such formulations (or similar formulations) in the concentration ranges indicated above for generally non-anionic bioactive agents.

权利要求:
Claims (15)
[1]
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65

Claims
1. A composition comprising:
i. a polyethylene oxide-polypropylene oxide block polymer surfactant of the formula:
HO ------- (CH2CH, OH) x ----- (CHCH20) v ----- (CH2CH, 0) x - H
‘I
ch3,
where "x" represents the average number of polyethylene oxide units and is an integer from 10 to 100; "Y" represents the average number of polypropylene oxide units and is an integer less than or equal to 30; and the ratio of "x" and "y" is 0.8: 1 to 4: 1;
ii. one or more non-anionic bioactive agents having a log P greater than 2; Y
iii. at least one orally acceptable solvent,
where the pH of the composition is maintained in a range below 5.
[2]
2. The compositions according to Claim 1 wherein x is an integer from 10 to 80.
[3]
3. The compositions according to Claim 2 wherein x is an integer from 16 to 80.
[4]
4. The compositions according to Claim 1 wherein y is an integer from 16 to 30.
[5]
5. The compositions according to Claim 1 wherein the ratio of "x" to "y" is not greater than 3: 1,
optionally where the ratio of "x" with y "is not greater than 2.8: 1.
[6]
6. The composition according to Claim 5 wherein the ratio of "x" to "y" is approximately 2.7: 1 or where the ratio of "x" to "y" is approximately 1: 1.
[7]
7. The compositions according to Claim 1 wherein the poloxamer is selected from the group consisting of poloxamer 108, poloxamer 188 or mixtures thereof, optionally wherein the poloxamer is poloxamer 188.
[8]
8. The compositions according to Claim 1 wherein one or more non-anionic bioactive agents is a bioactive essential oil.
[9]
9. The compositions according to Claim 8 wherein the bioactive essential oil is selected from the group consisting of thymol, eucalyptol, methanol, methyl salicylate and mixtures thereof, optionally where the bioactive essential oil is a mixture of thymol, eucalyptol, Menthol and methyl salicylate.
[10]
10. The composition according to Claim 1 wherein the composition is essentially free of C2-C4 monohydric alcohols.
[11]
11. The composition according to claim 10 wherein the composition is free of monohydric alcohols
C2-C4.
[12]
12. The composition according to Claim 1 wherein the composition is an oral composition.
[13]
13. The composition of Claim 1 for use in a method of treating plaque, gingivitis, pyorrhea or oral foul odor, comprising the step of applying a quantity of such a quantity to the oral cavity tissues of a mammal in need of such treatment. The composition of claim 1 effective for reducing symptoms associated with plaque, gingivitis, pyorrhea or oral odor.
[14]
14. The composition of Claim 1 for use in a method of reducing the number of oral microorganisms responsible for plaque, gingivitis, pyorrhea or oral malodor, which comprises the step of applying to the tissues of the oral cavity of a mammal that such microorganisms have an amount of the composition of claim 1 effective in reducing the number of such oral microorganisms.
[15]
15. The composition for use according to Claim 14 wherein the application of the composition results in an M factor greater than about 0.5.

类似技术:

公开号 | 公开日 | 专利标题

BRPI0518655B1|2015-09-08|oral composition for the treatment, inhibition or reduction of an oral inflammatory condition

ES2236752T3|2005-07-16|ANTIMICROBIAL COMPOSITIONS CONTAINING A C3-C6 ALCOHOL.

JP6704731B2|2020-06-03|Oral care composition

US10130576B2|2018-11-20|Oral care compositions

ES2648235T3|2017-12-29|Compositions for oral care

CA2888998C|2021-06-29|Oral care compositions comprising a phospholipid surfactant

同族专利:

公开号 | 公开日

RU2015141070A|2017-03-31|

WO2014133746A3|2014-10-23|

JP2016509055A|2016-03-24|

CN105142601A|2015-12-09|

US20140242004A1|2014-08-28|

RU2686698C2|2019-04-30|

JP6441241B2|2018-12-19|

CA2900381A1|2014-09-04|

BR112015020053B1|2020-05-26|

WO2014133746A2|2014-09-04|

CN105142601B|2018-01-05|

AU2014221347A1|2015-08-13|

EP2961373B9|2018-04-11|

CA2900381C|2021-06-29|

ES2648235T3|2017-12-29|

US9072687B2|2015-07-07|

EP2961373B1|2017-11-01|

EP2961373A2|2016-01-06|

NO3060906T3|2017-12-30|

BR112015020053A2|2017-07-18|

MX349487B|2017-07-31|

MX2015011053A|2016-03-01|

AU2014221347B2|2018-05-10|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US3959458A|1973-02-09|1976-05-25|The Procter & Gamble Company|Oral compositions for calculus retardation|

US4051234A|1975-06-06|1977-09-27|The Procter & Gamble Company|Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies|

GR79663B|1981-06-26|1984-10-31|Colgate Palmolive Co|

US5066483A|1989-03-13|1991-11-19|Vipont Pharmaceutical, Inc.|Oral rinse compositions|

US5116602A|1989-09-27|1992-05-26|Colgate-Palmolive Company|Antiplaque oral compositions|

US5190747A|1989-11-06|1993-03-02|Lion Corporation|Oral or detergent composition comprising a nonionic surface active agent|

JP3136421B2|1991-11-14|2001-02-19|アース製薬株式会社|Cetylpyridinium stabilizer|

AU682489B2|1993-01-27|1997-10-09|Warner-Lambert Company|Reduced alcohol mouthwash antiseptic and antiseptic preparations|

CA2143037C|1994-05-02|2002-04-30|Atma Chaudhari|Alcohol free mouthwash|

US5599527A|1994-11-14|1997-02-04|Colgate-Palmolive Company|Dentifrice compositions having improved anticalculus properties|

AU3890395A|1994-11-17|1996-06-17|Warner-Lambert Company|Antimicrobial oral compositions|

US5624906A|1994-12-08|1997-04-29|Lever Brothers Company, Division Of Conopco, Inc.|Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds|

US5912228A|1995-01-13|1999-06-15|Xoma Corporation|Therapeutic compositions comprising bactericidal/permeability-increasing protein products|

US5874068A|1997-12-08|1999-02-23|Warner-Lambert Company|Stabilized antiplaque and antigingivitis oral compositions containing N.sup.α -alkyl-L-arginine alkyl ester salts|

US6218438B1|1998-11-18|2001-04-17|Supratek Pharma, Inc.|Copolymer compositions for treating viral infections|

AU1043302A|2000-07-26|2002-02-05|Boots Co Plc|Dental compositions|

FR2830759B1|2001-10-15|2003-12-12|Oreal|COMPOSITION IN THE FORM OF AN OIL-IN-WATER EMULSION CONTAINING A SILICONE COPOLYMER AND ITS IN PARTICULAR COSMETIC USES|

US6689342B1|2002-07-29|2004-02-10|Warner-Lambert Company|Oral care compositions comprising tropolone compounds and essential oils and methods of using the same|

US7084104B2|2003-08-28|2006-08-01|Johnson & Johnson Consumer Company Inc.|Mild and effective cleansing compositions|

IL159729D0|2004-01-06|2004-06-20|Doron I Friedman|Non-aqueous composition for oral delivery of insoluble bioactive agents|

US20060198797A1|2005-11-07|2006-09-07|Giniger Martin S|Stand-alone or enhancer composition for oral care|

US8273385B1|2008-10-17|2012-09-25|Thres Flo, LLC|Oral rinse composition and method|

AU2010292276B2|2009-09-11|2014-07-17|The Procter & Gamble Company|Methods and compositions for hydrophobic modification of oral cavity surfaces|

US9591852B2|2009-11-23|2017-03-14|Mcneil-Ppc, Inc.|Biofilm disruptive compositions|

US20120003162A1|2010-06-30|2012-01-05|Mcneil-Ppc, Inc.|Methods of Preparing Non-Alcohol Bioactive Esential Oil Mouth Rinses|

US9084902B2|2010-06-30|2015-07-21|Mcneil-Ppc, Inc.|Non-alchohol bioactive essential oil mouth rinses|US20190083366A1|2017-09-19|2019-03-21|Marlinspike Group, Inc.|Mouthwash granules for an aqueous solution|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

US13/777,451|US9072687B2|2013-02-26|2013-02-26|Oral care compositions|

US201313777451|2013-02-26|

PCT/US2014/015727|WO2014133746A2|2013-02-26|2014-02-11|Oral care compositions|

[返回顶部]